Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2017, 42(5): 305
ISSN 0377-8282
Copyright 2017 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2017.042.05.2630640
 
 
Cambridge Healthcare Institute's Second Annual Immuno-Oncology Summit Europe
Jago, C.
 
 
Cambridge Healthcare Institute (CHI)'s second annual Immuno- Oncology Summit Europe, held in London, U.K., comprised three sequential conference tracks focusing on different areas of research in the highly dynamic immuno-oncology field. The summit began with novel approaches to cancer, moved on to immunomodulatory approaches, and concluded with combination immunotherapy. The novel-approaches track concentrated heavily on chimeric antigen receptor (CAR) T-cell therapeutics, alongside modified T-cell receptor (TCR)- based approaches. The CAR T-cell topics discussed included the targeting of multiple ligands, new cell culture methods to enhance activity, two-CAR systems to prevent toxicity and cancer escape, and CAR-inducible cytokine release technology to enhance the antitumor innate response. Discussions around modified TCRs included TCR-improvement methods, methods of preclinical assessment, the use of T cells expressing more than one type of TCR in order to target tumors while also mitigating against tumor tolerance, and a MAGEtargeting TCR were also part of the track.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy